NCT07045454 - A Study of MHB118C Injection in Patients With Advanced Solid Tumors | Biotech Hunter

Enrollment

200

Participants

Timeline

Start Date

March 31, 2025

Primary Completion Date

March 31, 2029

Study Completion Date

March 31, 2031

Conditions

Advanced Malignant Solid Tumor

Interventions

DRUG

MHB118C for Injection

IV administration by Q3W; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.

Trial Locations (1)

Unknown

RECRUITING

Shanghai Chest Hospital, Shanghai